RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/th...

Full description

Saved in:
Bibliographic Details
Published in:Front Pharmacol
Main Authors: Honjo, Hajime, Watanabe, Tomohiro, Kamata, Ken, Minaga, Kosuke, Kudo, Masatoshi
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2021
Subjects:
Pharmacology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079979/
https://ncbi.nlm.nih.gov/pubmed/33935757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.650403
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items